You may remember that not so long ago I wrote about what looked like a drug discovery success story for pain: anti-NGF therapy for osteoarthritis. Well, it looks like that success was short-lived. Somehow I missed this over the Christmas break, but, the FDA has ended trials on anti-NGF therapies for osteoarthritis due to development of avascular necrosis in some patients. Nothing positive can come of avascular necrosis and the pulling of several trials would suggest that this is a drug class effect (or at least suspected to be). Anyway you cut it, this is bad news.
Error: Twitter did not respond. Please wait a few minutes and refresh this page.
theblueflowersblog on What is hyperalgesia? What is… Sheena on What is hyperalgesia? What is… Sheena on What is hyperalgesia? What is… Sheena on What is hyperalgesia? What is… Amplified Pain… on What is hyperalgesia? What is…
- 523,599 fans